Global reach and sustained engagement of a structured digital education program in medical mycology: an observational analysis of the 2025 ESCMID-EFISG webinar series - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Worldwide Impact and Ongoing Participation in a Structured Digital Learning Initiative for Medical Mycology: An Observational Study of the 2025 ESCMID-EFISG Webinar Series

  • By

  • Jon Salmanton-García

  • Lena Siewert

  • Malcolm Richardson

  • Antonio Vena

  • September 14, 2026

Share

  • 1

    The 2025 EFISG series delivered 17 webinars across four pillars: clinical management, diagnostics, epidemiology and public health, and antifungal resistance.

  • 2

    The series recorded 4,631 registrations from 1,372 unique participants, with a median live attendance rate of 39.3%.

  • 3

    Sessions were held predominantly on Wednesdays and Thursdays and had a median duration of 108 minutes.

  • 4

    The study assessed whether structured digital education could provide a scalable and equitable model for expanding access to specialized medical mycology expertise.

  • 5

    The study used aggregate platform-generated metadata to evaluate participation, engagement, geographic reach, and faculty characteristics.

Original Source(s)

Global reach and sustained engagement of a structured digital education program in medical mycology: an observational analysis of the 2025 ESCMID-EFISG webinar series

  • by Jon Salmanton-García, Lena Siewert, Malcolm Richardson, Antonio Vena

  • September 14, 2026

Related Content

A family and healthcare-associated cluster of severe fever with thrombocytopenia syndrome in Shanghai, China: an epidemiological investigation in a nonendemic area

4CMenB tied to modest gonorrhea protection in real-world study

The 38.4% reduction in gonorrhea risk “could translate into preventing a substantial number of infections and complications.”

Rethinking Infection Diagnostics in Cystic Fibrosis

A dedicated syndicate is connecting academia, industry, and people with cystic fibrosis to advance diagnostic research